Objective:To investigate the effects of hepatic fatty acid transporter 5 (FATP5) gene expression on the levels of free long-chain fatty acid (LCFA) in mice with metabolic associated fatty liver disease (MAFLD).Methods:From June to December 2022, a prospective study was conducted with three experimental groups: wild-type (WT) group, FATP5 gene expression negative (FATP5 -) group, and human FATP5 gene expression positive (hFATP5 +) group, with 10 mice in each group. Each group of mice was fed a high-fat diet for 16 weeks to establish a model of MAFLD. Hepatic tissue changes were observed using hematoxylin-eosin staining. The liver mass and liver coefficient of the mice were measured. Total cholesterol (TC), triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid (UA), and LCFA levels were determined using an automatic biochemical analyzer. Blood glucose (Glu) levels were measured using a blood glucose analyzer. The liver mass and liver coefficient, TC and TG levels, AST and ALT levels, Glu and UA levels, and LCFA levels were compared among the three groups. Results:In the WT group, there was significant inflammatory cell infiltration within the hepatocytes and a large amount of fat accumulation. In the FATP5 - group, the inflammatory cell infiltration in the hepatocytes was mild with slight fat accumulation. In the hFATP5 + group, the inflammatory cell infiltration in the hepatocytes was severe, with great fat accumulation. The liver mass [(1.27 ± 0.25) g], liver coefficient (2.38 ± 0.19), TC [(1.82 ± 0.26) mmol/L], TG [(0.93 ± 0.24) mmol/L], AST [(169.95 ± 37.73) U/L], ALT [(95.36 ± 21.49) U/L], Glu [(8.34 ± 1.52) mmol/L], and UA [(74.32 ± 15.52) μmol/L] in the FATP5 - group were all significantly lower than those in the WT group [(1.61 ± 0.23) g, (2.71 ± 0.20), (2.31 ± 0.28) mmol/L, (1.34 ± 0.21) mmol/L, (278.31 ± 43.24) U/L, (147.32 ± 28.81) U/L, (10.52 ± 1.24) mmol/L, (96.28 ± 17.43) μmol/L], while the LCFA level [(3.57 ± 0.48) mg/L] in the FATP5 - group was significantly higher than that in the WT group [(2.63 ± 0.56) mg/L] ( t = 3.17, 3.78, 4.06, 4.07, 5.97, 4.57, 3.51, 2.98, 4.03, all P < 0.05). In the hFATP5 + group, the liver mass [(1.92 ± 0.30) g], liver coefficient (2.95 ± 0.23), TC [(2.59 ± 0.24) mmol/L], TG [(1.76 ± 0.35) mmol/L], AST [(341.22 ± 48.98) U/L], ALT [(189.45 ± 17.97) U/L], Glu [(13.21 ± 1.98) mmol/L], and UA [(117.74 ± 18.38) μmol/L] were all significantly higher than those in the WT group, while the LCFA level [(3.57 ± 0.48) mg/L] in the FATP5 + group was significantly lower than that in the WT group ( t = 2.59, 2.49, 2.40, 3.25, 3.04, 3.92, 3.64, 2.68, 3.19, all P < 0.05). Conclusions:The absence of FATP5 in the liver can elevate blood levels of LCFA in mice with MAFLD, reduce food intake, and help alleviate the symptoms of MAFLD.

Objective:To investigate the effects of hepatic fatty acid transporter 5 (FATP5) gene expression on the levels of free long-chain fatty acid (LCFA) in mice with metabolic associated fatty liver disease (MAFLD).Methods:From June to December 2022, a prospective study was conducted with three experimental groups: wild-type (WT) group, FATP5 gene expression negative (FATP5 -) group, and human FATP5 gene expression positive (hFATP5 +) group, with 10 mice in each group. Each group of mice was fed a high-fat diet for 16 weeks to establish a model of MAFLD. Hepatic tissue changes were observed using hematoxylin-eosin staining. The liver mass and liver coefficient of the mice were measured. Total cholesterol (TC), triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid (UA), and LCFA levels were determined using an automatic biochemical analyzer. Blood glucose (Glu) levels were measured using a blood glucose analyzer. The liver mass and liver coefficient, TC and TG levels, AST and ALT levels, Glu and UA levels, and LCFA levels were compared among the three groups. Results:In the WT group, there was significant inflammatory cell infiltration within the hepatocytes and a large amount of fat accumulation. In the FATP5 - group, the inflammatory cell infiltration in the hepatocytes was mild with slight fat accumulation. In the hFATP5 + group, the inflammatory cell infiltration in the hepatocytes was severe, with great fat accumulation. The liver mass [(1.27 ± 0.25) g], liver coefficient (2.38 ± 0.19), TC [(1.82 ± 0.26) mmol/L], TG [(0.93 ± 0.24) mmol/L], AST [(169.95 ± 37.73) U/L], ALT [(95.36 ± 21.49) U/L], Glu [(8.34 ± 1.52) mmol/L], and UA [(74.32 ± 15.52) μmol/L] in the FATP5 - group were all significantly lower than those in the WT group [(1.61 ± 0.23) g, (2.71 ± 0.20), (2.31 ± 0.28) mmol/L, (1.34 ± 0.21) mmol/L, (278.31 ± 43.24) U/L, (147.32 ± 28.81) U/L, (10.52 ± 1.24) mmol/L, (96.28 ± 17.43) μmol/L], while the LCFA level [(3.57 ± 0.48) mg/L] in the FATP5 - group was significantly higher than that in the WT group [(2.63 ± 0.56) mg/L] ( t = 3.17, 3.78, 4.06, 4.07, 5.97, 4.57, 3.51, 2.98, 4.03, all P < 0.05). In the hFATP5 + group, the liver mass [(1.92 ± 0.30) g], liver coefficient (2.95 ± 0.23), TC [(2.59 ± 0.24) mmol/L], TG [(1.76 ± 0.35) mmol/L], AST [(341.22 ± 48.98) U/L], ALT [(189.45 ± 17.97) U/L], Glu [(13.21 ± 1.98) mmol/L], and UA [(117.74 ± 18.38) μmol/L] were all significantly higher than those in the WT group, while the LCFA level [(3.57 ± 0.48) mg/L] in the FATP5 + group was significantly lower than that in the WT group ( t = 2.59, 2.49, 2.40, 3.25, 3.04, 3.92, 3.64, 2.68, 3.19, all P < 0.05). Conclusions:The absence of FATP5 in the liver can elevate blood levels of LCFA in mice with MAFLD, reduce food intake, and help alleviate the symptoms of MAFLD.

Objective To investigate the effect of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary hepatocellular carcinoma (HCC) and its influence on the levels of nuclear factor kappa B (NF-B) and p53.Methods 90 patients with primary HCC were selected,and they were randomly divided into control group (n =45) and observation group (n =45) according to the digital table.The control group received chemoembolization treatment,the observation group was given combined radiofrequency ablation treatment.The patients were continuously treated for 6 months.Immunohistochemical assay was used to detect the expression of NF-B and p53 in two groups.The clinical curative effect and influence on the expression of NF-B and p53 were compared between the two groups.Results After 6 months of treatment,the Karnofsky score of the observation group was (84.32 ± 12.31)points,which was higher than (64.32 ± 11.24) points of the control group (t =21.295,P ＜ 0.05).After treatment for 6 months,the AFP level of the observation group was (121.23 ± 1.43) μg/L,which was lower than (189.44 ± 36.42) μg/L of the control group (t =19.853,P ＜ 0.05).After treatment,the positive expression rates of NF-B and p53 of the observation group were 24.44％ and 20.00％,respectively,which were lower than 40％ and 33.33 ％ of the control group (x2 =6.597,5.784,all P ＜ 0.05).The recurrence rate of the observation group was 15.56％,which was lower than 28.89％ of the control group (x2 =6.126,P ＜ 0.05).The 6-month and 12-month survival rates of the observation group were 86.67％ and 82.22％,respectively,which were higher than 75.56％ and 64.44％ of the control group (x2 =4.927,7.192％,all P＜0.05).Conclusion The effect of radiofrequency ablation combined with radiofrequency ablation for patients with primary liver cancer is satisfactory,which is worthy of popularization and application.

Objective To evaluate the efficacy of entecavir treatment in chronic hepatitis B virus ( HBV ) infected patients with mild hepatic dysfunction and marked pathological injury.Methods One hundred and fifty five chronic hepatitis B ( CHB) patients with HBV DNA>1.0 ×104 U/mL admitted in Lishui People’ s Hospital during January 2008 to October 2011 were enrolled in the study.Patients were divided into three groups: those with serum ALT <2 ×ULN and liver inflammation injury ≥G2 and/or fibrosis stage≥S2 were in observation group ( n=75 ); patients with ALT ( 2-5 ) ×ULN were in control group 1 (n=38);patients with ALT>5 ×ULN were in control group 2 (n=42).All patients were given entecavir (0.5 mg, 1/d, p.o) treatment.ALT normalization rates, HBV DNA negative rates, HBeAg negative conversion rates and seroconversion rates at 12-, 24-,48-, 96-and 144-week were observed and compared among groups.Variance analysis andχ2 test were performed for measurement data and numeration data, respectively.Results ALT normalization rates in observation group were 86.7%, 90.7%, 90.7%, 92.0%and 96.0%at 12-, 24-, 48-, 96-and 144-week, which were higher than those in control group 1 (χ2 =2.04, 2.15, 2.78, 2.69 and 2.47, P <0.01), but no statistically significant difference was observed between observation group and control group 2 (χ2 =2.53,2.42,2.09,2.24 and 2.32,P>0.05) . HBV DNA negative rates in observation group were 70.7%, 78.7%and 82.7%at 12-, 24-and 48-week, which were higher than those in control group 1 (χ2 =4.56, 4.23 and 4.28, P<0.05), but no statistically significant difference was observed between observation group and control group 2 (χ2 =2.75, 2.62 and 2.98, P>0.05).HBeAg negative conversion rates in observation group were 6.6%, 21.3%and 25.3%at 48-, 96-, and 144-week, which were higher than those in control group 1 (χ2 =4.68, 4.78 and 5.01, P<0.05), but no statistically significant difference was observed between observation group and control group 2 (χ2 =2.24, 2.57 and 2.13, P>0.05).HBeAg seroconversion rate in observation group was 4.0%at 24-week, which were higher than that in control group 1 (χ2 =2.87, P <0.05), but the seroconversion rates at 96-and 144-week were lower than those in control group 2 (χ2 =2.92 and 3.14, P<0.05).Conclusion The efficacy of entecavir treatment for HBV infected patients with mild hepatic dysfunction and marked pathological injury is satisfactory.